Product Description
Mechanisms of Action: V2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Inappropriate ADH Syndrome|Liver Cirrhosis|Hyponatremia|Diabetes Insipidus|Heart Failure
Phase 2: Liver Cirrhosis|Hyponatremia|Inappropriate ADH Syndrome|Diabetes Insipidus
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2006-005753-29 |
PASCCAL-1 | P2 |
Completed |
Liver Cirrhosis |
2008-12-03 |
2022-03-12 |
Treatments |
|
NCT00501384 |
SPA | P2 |
Completed |
Liver Cirrhosis |
2005-05-01 |
2019-03-21 |
Treatments |
|
NCT00501722 |
Hypo~CAT | P2 |
Completed |
Liver Cirrhosis|Hyponatremia |
2005-03-01 |
2019-03-21 |
Treatments |
|
NCT00501566 |
Normo~CAT | P2 |
Completed |
Liver Cirrhosis |
None |
2019-03-21 |
Treatments |
|
NCT00032734 |
DFI4488 | P2 |
Completed |
Hyponatremia|Inappropriate ADH Syndrome|Diabetes Insipidus |
None |
2019-03-21 |
Treatments |
|
2006-000135-10 |
SPARe-2 | P3 |
Completed |
Liver Cirrhosis |
2009-03-03 |
2022-03-12 |
Treatments |
|
2006-000132-27 |
CATS | P3 |
Completed |
Liver Cirrhosis |
2008-12-30 |
2022-03-12 |
Treatments |
|
NCT00358878 |
CATS | P3 |
Completed |
Liver Cirrhosis |
2008-12-01 |
2019-03-21 |
Treatments |
|
NCT00366795 |
SPARe-2 | P3 |
Terminated |
Liver Cirrhosis |
2008-12-01 |
2019-03-21 |
||
NCT00728091 |
AQUARIST1 | P3 |
Terminated |
Hyponatremia|Inappropriate ADH Syndrome |
2008-12-01 |
2019-03-18 |
Treatments |
|
2007-007941-10 |
AQUARIST I | P3 |
Terminated |
Inappropriate ADH Syndrome|Hyponatremia |
2008-11-10 |
2022-03-12 |
Treatments |
|
NCT00359437 |
SPARe-1 | P3 |
Terminated |
Liver Cirrhosis |
2008-10-01 |
2024-06-26 |
Primary Endpoints|Treatments |
|
2006-006521-30 |
PASCCAL-2 | P3 |
Terminated |
Liver Cirrhosis |
2008-09-26 |
2022-03-12 |
Treatments |
|
2006-000134-12 |
SPARe-1 | P3 |
Terminated |
Liver Cirrhosis |
2008-09-12 |
2022-03-12 |
Treatments |
|
2006-005422-23 |
2006-005422-23 | P3 |
Completed |
Hyponatremia |
2008-05-15 |
2022-03-12 |
Treatments |
|
2004-002349-11 |
SIADH | P3 |
Completed |
Inappropriate ADH Syndrome |
2007-09-27 |
2022-03-12 |
Treatments |
|
NCT00264927 |
SIADH | P3 |
Completed |
Inappropriate ADH Syndrome|Diabetes Insipidus|Hyponatremia |
2007-09-01 |
2019-03-21 |
Treatments |
|
2004-005239-25 |
SIADH Safety | P3 |
Completed |
Inappropriate ADH Syndrome |
2007-08-28 |
2022-03-12 |
Treatments |
|
NCT00264914 |
SIADH Safety | P3 |
Completed |
Inappropriate ADH Syndrome|Diabetes Insipidus|Hyponatremia |
2007-08-01 |
2019-03-21 |
Treatments |
|
2004-003985-14 |
Dilutional Hyponatremia | P3 |
Completed |
Liver Cirrhosis|Inappropriate ADH Syndrome|Hyponatremia |
2007-07-18 |
2022-03-12 |
Treatments |
|
NCT00274326 |
DILutIonal HyPOnatremia | P3 |
Completed |
Hyponatremia|Heart Failure |
2007-07-01 |
2019-03-21 |
Treatments |